KPI-150 is a novel topical cream formulation from the same family of compounds as dalazatide. This product opportunity is focused on topical applications such as atopic dermatitis and psoriasis where safer, more effective, and durable treatments are severely needed.
Therapeutic Need – Atopic Dermatitis
Atopic Dermatitis is a chronic inflammatory autoimmune skin disease that affects over 15 million people in the USA alone. More than half of those patients are under the age of 20. The current treatment options such as moisturizers and corticosteroids only address the symptoms of the disease and stronger immunosuppressive drugs can have debilitating side effects. Even with current therapeutic options these patients still have many unmet needs.
Immunohistochemistry analysis has demonstrated that the infiltrating T cells in atopic dermatitis express high levels of the Kv1.3 channel and are thus a good target for KPI-150 treatment.
KPI-150 has already been validated in topical in vivo efficacy models. KPI-150 demonstrated dose-dependent activity in an atopic dermatitis model where the drug was able to reduce inflammation, T cell infiltration, and markers of inflammation when applied topically. Based upon non-clinical models we anticipate KPI-150 will be well tolerated. Drug formulation optimization and skin penetration assessments are ongoing to further develop KPI-150 for dermatologic applications.